Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.61 (
caspase-8
)
6,833
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The regulation of caspases, cysteine proteinases that cleave their substrates after aspartic residues, is poorly understood, even though they are involved in tightly regulated cellular processes. The recently discovered serpin analogue
proteinase inhibitor 9
(
PI9
) is unique among human serpin analogues in that it has an acidic residue in the putative specificity-determining position of the reactive-site loop. We measured the ability of
PI9
to inhibit the amidolytic activity of several caspases. The hydrolysis of peptide substrates by caspase-1 (interleukin-1beta-converting enzyme), caspase-4 and
caspase-8
is inhibited by
PI9
in a time-dependent manner. The rate of reaction of caspase-1 with
PI9
, as well as the rate of substrate hydrolysis of the initial caspase-
PI9
complex, shows a hyperbolic dependence on the concentration of
PI9
, indicative of a two-step kinetic mechanism for inhibition with an apparent second-order rate constant of 7x10(2) M(-1).s(-1). The hydrolysis of a tetrapeptide substrate by caspase-3 is not inhibited by
PI9
. The complexes of caspase-1 and caspase-4 with
PI9
can be immunoprecipitated but no complex with caspase-3 can be detected. No complex can be immunoprecipitated if the active site of the caspase is blocked with a covalent inhibitor. These results show that
PI9
is an inhibitor of caspase-1 and to a smaller extent caspase-4 and
caspase-8
, but not of the more distantly related caspase-3.
PI9
is the first example of a human serpin analogue that inhibits members of this class of cysteine proteinases.
...
PMID:Caspase-1 (interleukin-1beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. 1047 77